Press Release

SOUTHPORT, N.C. (September 26, 2019) - Cygnus Technologies, a Maravai LifeSciences company, announced today that it has achieved ISO 9001:2015 certification. This designation certifies a high level of quality assurance and consistency and will be particularly important to Cygnus Technologies customers engaged in biotherapeutics manufacturing.

ISO is the International Organization for Standardization, and certification is a demonstration of Cygn...

MINNEAPOLIS, M.N. and SOUTHPORT, N.C. (August 12, 2019) - PRNewswire/ -- Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced today a strategic partnership for the quantification of Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple™-branded Ella™ immunoassay platform. Under the terms of the agreement, Bio-Techne and Cygnus are introducing the co-developed third generation CHO-HCP assay in the proprietary Simple...

SOUTHPORT, N.C. (June 24, 2019) - Cygnus Technologies, a Maravai LifeSciences company, announces an expansion of its service offerings for host cell protein (HCP) analysis. A pioneer in tools for the detection of HCP impurities in biopharmaceuticals and vaccines, Cygnus now offers services to identify and quantify those impurities, which can impact the efficacy and stability of the...

SOUTHPORT, N.C. (April 18, 2019) - Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, introduces the EndonucleaseGTP™ ELISA Kit for the detection and quantitation of residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. Endonucleases such as Benzonase* and Denarase* are oft...

SOUTHPORT, N.C. (September 6, 2017) - Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, announced today that it has selected DBA Italia S.r.l. to distribute its products in Italy. DBA Italia has a 34-year track record, serving customers in biomedical research, immunology, biochemistry, molecular biology, microbiology,...

SOUTHPORT, N.C. (June 19, 2017) -  Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, announced today that it has selected Bio-Connect BV to distribute the company’s products in The Netherlands, Belgium and Luxembourg.

“Bio-Connect BV is a dynamic company with excellent coverage of the life science res...

BURLINGAME, Calif. (October 20, 2016) -  Maravai LifeSciences, a transformative company in the life science research market, announced today that it has acquired Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaeuticals. The acquisition fits with Maravai LifeSciences’ goal of creating a...

SOUTHPORT, N.C. (May 12, 2015) - Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, announced today a new Antibody Affinity Extraction™ (AAE) method for the detection of individual proteins in biotherapeutic products. A superior alternative to 2D western blot methods, AAE is estimated to be 100 times more sensit...

Contacts for the media

Jennifer Dahlgren 
Dahlgren Communications 
Phone: (530) 263-6817 
Email: [email protected]

David Weber, Chief Commercial Officer
Maravai LifeSciences 
Phone: (650) 697-3600 
Email: [email protected]